Company profile: MaxiVAX
1.1 - Company Overview
Company description
- Provider of clinical-stage cancer immunotherapies and cell-encapsulation delivery platforms, including MVX-ONCO-1 for recurrent/metastatic head and neck squamous carcinoma, Encapsulated Cell Technology for sustained, controlled protein delivery (e.g., low-dose anti-CTLA-4 in a colorectal cancer model), and MVX-ONCO-2, a second-generation personalized immunotherapy for advanced solid tumors.
Products and services
- Encapsulated Cell Technology: Platform technology that engineers sustained, controlled delivery of therapeutic proteins, demonstrated with low-dose anti-CTLA-4 in a colorectal cancer model
- MVX-ONCO-1: Phase IIa clinical-stage immunotherapy engineered to treat recurrent/metastatic Head and Neck Squamous Carcinoma, constructed as a dedicated clinical study for this defined tumor population
- MVX-ONCO-2: Second-generation personalized immunotherapy for advanced solid tumors, utilizing cell encapsulation technology for GMCSF delivery to patients in oncologic settings
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to MaxiVAX
Accession Therapeutics
HQ: United Kingdom
Website
- Description: Provider of immuno-oncology therapeutics based on Trocept, a stealth virus platform engineered to selectively enter cancer cells while bypassing healthy cells to deliver broad, potent payloads and minimize systemic toxicity, targeting hard-to-treat cancers. Pipeline includes TROCEPT-01 (immune checkpoint inhibitor), TROCEPT-02 (universal bispecific immune activator), and other targeted programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Accession Therapeutics company profile →
Miroculus
HQ: United States
Website
- Description: Provider of hands-off sample-to-answer solutions for molecular testing, delivering assay flexibility and automation via an affordable digital microfluidics platform that enables seamless workflow integration from novel molecular protocols to data analytics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Miroculus company profile →
Ariad Pharmaceuticals
HQ: United States
Website
- Description: Provider of oncology medicines, focused on the discovery, development and commercialization of treatments for cancer patients, including Iclusig for certain types of leukemia targeting cancer cells with specific genetic mutations; based in Cambridge, Massachusetts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ariad Pharmaceuticals company profile →
Cinfa Biotech
HQ: Spain
Website
- Description: Provider of biosimilars development and manufacturing exclusively in Europe, adhering to strict guidelines and highest European quality standards with specialist know-how. Founded in 2013 as part of the Spanish Cinfa Group; active in the global biosimilars market and currently has two products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cinfa Biotech company profile →
Myriad Genetics
HQ: United States
Website
- Description: Provider of genetic testing and molecular profiling solutions, including hereditary cancer risk assessment (MyRisk), pharmacogenomic testing for mental health medications (GeneSight), prostate cancer aggressiveness evaluation (Prolaris), tumor genomic profiling (Precise), carrier screening (Foresight), and non-invasive prenatal screening (Prequel).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Myriad Genetics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for MaxiVAX
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to MaxiVAX
2.2 - Growth funds investing in similar companies to MaxiVAX
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for MaxiVAX
4.2 - Public trading comparable groups for MaxiVAX
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →